Noticias y vídeos - FARON PHARMACEUTICALS OY ORD NPV (DI) - Página 2

ODD further strengthens bexmarilimab program by offering clinical development and commercialization benefits Expected completion of dose escalation, readout of enrichment cohorts, and Phase II initiation in Q4 2023 TURKU, Finland and BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces the U.S. Food and Drug Administration (FDA) has...

TURKU, Finland and BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will report its unaudited half-year financial results for the six months ended June 30, 2023, on Tuesday, August 29, 2023. A live virtual briefing and Q&A session for investors, analysts and media will be hosted by Dr. Markku Jalkanen, Chief Executive Officer, and James O’Brien,...

TURKU, Finland and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, will hold a conference call today to discuss new positive clinical data from the Company's ongoing Phase I/II BEXMAB study. Conference Call and Webcast Wednesday, July 19, 2023, at 8:30 am ET . The live call may be accessed by dialing (877) 407-3982 for callers in the US and (201)...

Three of five patients in the 6 mg/kg bexmarilimab + azacitidine doublet cohort achieved objective responses (CR and mCR) Eight of 15 objective responses observed in all three doublet dosing cohorts One patient has stayed on treatment for 13 months Updated BEXMAB data supports advancement to Phase II in H2 2023 focusing on SoC relapsed/refractory AML and MDS patients failing hypomethylating agents (HMA) Filing of first Biologics License Application (BLA) to FDA planned for H1 2025 Company...

Faron Pharmaceuticals Ltd ("Faron" or the "Company") Interim Results for the six months ended 30 June 2017 INTEREST Phase III Traumakine ® trial patient recruitment to complete in Q4 2017 and FDA advice received regarding advancement to BLA Traumakine clinical development broadened to include organ protection opportunities Clevegen ® advancing towards clinic TURKU - FINLAND, 6 September 2017 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, today...

Faron Pharmaceuticals Ltd ("Faron" or the "Company") Faron announces that US FDA proposes proceeding directly to BLA submission for Traumakine ® following completion of European and Japanese Phase III studies TURKU - FINLAND, 4 September 2017 - Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, today announces that the FDA has proposed that Faron can proceed directly to Biologics License Application (BLA) submission pending positive results from the...

Faron Pharmaceuticals Ltd ("Faron" or the "Company") Final Results for the year ended 31 December 2016 TURKU - FINLAND, 29 March 2017 Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, today reports its full year audited results for the year ended 31 December 2016. The 2016 Annual Report and Accounts become available in mid-April in digital form on the Company's website together with the invitation to the Annual General Meeting (AGM). HIGHLIGHTS...

Xerfi Canal TV a reçu Olivier Faron, Administrateur général du Conservatoire national des arts et métiers, dans le cadre du Forum "Tout changer!" organisé par Le Cnam et La Tribune. Une interview menée par Thibault Lieurade....